Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396495 | 1.00 | ABCB1 (0.50) | ABCB1HTR2CMEN1KMT2APOLL | |
| Phosphine SCHEMBL11895753 | 0.93 | ABCB1 (0.45) | ABCB1HTR2CMEN1KMT2APOLL | |
| SCHEMBL28204910 | 0.85 | ABCB1 (0.60) | ABCB1HTR2CMEN1KMT2APOLL | |
| SCHEMBL21820012 | 0.85 | ABCB1 (0.43) | ABCB1HTR2CMEN1KMT2APOLL | |
| SCHEMBL29392064 | 0.84 | ADRA2A (0.41) | ABCB1HTR2CHTR1APTGDR2 | |
| SCHEMBL22275 | 0.84 | ABCB1 (0.47) | ABCB1HTR2CMEN1KMT2APOLL | |
| SCHEMBL30645476 | 0.84 | HTR1A (0.42) | ABCB1HTR2CMEN1KMT2APOLL | |
| SCHEMBL27901929 | 0.84 | ABCB1 (0.46) | ABCB1MEN1KMT2ADRD2HTR1A | |
| SCHEMBL21820014 | 0.81 | HTR2C (0.43) | ABCB1HTR2CMEN1KMT2APOLL | |
| SCHEMBL28167754 | 0.79 | ABCB1 (0.42) | ABCB1MEN1KMT2APOLLDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813600-A | Organic electroluminescent material and device thereof | 北京夏禾科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3412660-B9 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO LTD (JP) | 2021-04-14 | — | — | EP | disclosed |
| EP-3412660-B1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO LTD (JP) | 2020-11-18 | — | — | EP | disclosed |
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | EA PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3412660-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA Pharma Co., Ltd. (JP) | 2018-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | ITGB4, ITGB7, ITGA4 | ABCB1 726/4885HTR2C 2886/4885MEN1 4090/4885 |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ITGB4, ITGB5, ITGA4 | ABCB1 617/4885HTR2C 1752/4885MEN1 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.